度普利尤单抗用于2型炎症性皮肤疾病的研究进展
Progress in dupilumab for type 2 inflammatory skin disorders
赵玉婷 1宋沧桑 1王国徽 2张函舒2
作者信息
- 1. 昆明市第一人民医院药学部,昆明 650000;昆明医科大学附属甘美医院,昆明 650000
- 2. 昆明市第一人民医院药学部,昆明 650000
- 折叠
摘要
中国人皮肤疾病患病率高达40％～70％,其中2型炎症性皮肤疾病发病率超过10％.传统治疗方案包括糖皮质激素联合抗组胺药或免疫抑制剂,存在病情控制不佳、药物不良反应多等弊端.靶向生物制剂度普利尤单抗的研发上市,为2型炎症性皮肤疾病提供了全新的治疗选择,但临床上度普利尤单抗常超适应证应用于其他2型炎症性皮肤疾病的治疗.本文就近年来度普利尤单抗在2型炎症性皮肤疾病中的应用研究进展进行综述,以期为该类患者的治疗提供新思路并且对生物制剂的临床应用进行展望.
Abstract
The prevalence of skin disorders in China is as high as 40％～70％,with the incidence rate of type 2 inflammatory skin disease exceeding 10％.Traditional treatment options include glucocorticoids combined with antihistamines or immunosuppressants,which may have drawbacks such as poor disease control and various adverse drug reactions.The development and marketing of dupilumab has provided a new therapeutic option for type 2 inflammatory skin diseases,but dupliumab is often used off-label for other type 2 inflammatory skin diseases clinically.In this review,the application of dupliumab in type 2 inflammatory skin diseases in recent years was reviewed,with a view to providing new ideas for the treatment of this type of patients and looking forward to the clinical application of biologics.
关键词
2型炎症性皮肤疾病/度普利尤单抗/靶向生物制剂/超适应证Key words
type 2 inflammatory skin disease/dupilumab/targeted biologics/over-indication引用本文复制引用
基金项目
云南省临床药学中心建设项目()
云南省卫生健康委医学领军人才培养计划(L-2018012)
昆明市医学科技领军人才培养项目(2023-SW领军-04)
出版年
2024
NETL
NSTL
万方数据